Forward
- Apr 28
- 9 min read
Updated: Jun 3
To improve outcomes, it seems helpful to convince every clinician that amazing things can be done to improve health, surmount disease, counteract detrimental conditions and circumstances, assure vital being, and ensure indefinite sustainability of vital being. The following artifacts might be password protected. Use vitrupath as the authentication phrase.
The authentication phrase to view documents = vitrupath
Begin the Abatement and Eradication of Disease
This review has found that a 20% protein nutritional regimen and a requirement of between 4 and 7 mg per kg of anatomical mass for choline or choline metabolites is essential. Utilizing raw or uncooked sources for both of these nutrients is crucial, as cooking deteriorates molecular structure. Given that the absorption rate of nutritionally obtained aspects of these nutrients is approximately 5%, it indicates the necessity for a clinical preparation that has been pharmacologically enhanced for absorption. The hydrogen anion version of hydrogen must be protected from attenuation and deterioration through proper preparation, packaging, or storage routines. There may be other factors presented in this document that require similar or different protection.
Minimal Daily Routine
A. Enlyte or EnlyteRX (essential)
B. Lecithin with Vitamin K2 (essential)
C. Grapeseed extract and probiotic such as Align or leaky gut therapy (essential) and a regularly administered laxative at least once or optimally twice a month
D. L-arginine, L-citrulline, L-ornithine
E. Diverse mineral supplement with molybdenum, cobalt, iodide, calcium, vanadium (essential)
F. Diverse multivitamin with B12 methylcobalamin, Vitamin K2, Vitamin D, and Folate (essential)
G. Low intensity, short duration exercise using resistance (essential)
H. EMF protection bedding, clothing, and dwelling protection (power outlets, appliances, and devices) (essential)
I. DHA docosahexaenoic acid
J. ARA arachidonic acid at levels higher than DHA obtainment
K. Diverse omega-3, omega-6, and omega-9 fatty acid or cholesterol supplement
L. Whole animal glandular, micronized into fine granularity
M. Bone powder
N. Sodium, preferably as ancient pink Himalayan sea salt
O. Rezdiffera or Resmitirom for the prevention of liver adiposity, which might also be diminished using Vitamin E, Pioglitazone, Metformin, cholesterol-lowering therapy, pentoxifylline, and angiotensin receptor inhibitors
Repressing Tfam with Nobiletin while assuring that Tfam is actually expressed, activity of cystathionine gamma lyase, rapamycin obtainment, NAD+ supplementation as potentiators such as Niagen, methylene cysteine lower than 6 μm/L toward 3.7 μm/L, and dimethylglycine all contribute to mitigating the diminished aspects of advancing age.
More Information on the Minimal Daily Routine
A. Minimum Supplements at More Foundational Levels:
Enlyte presented on drugs.com or Enlyte with Deltafolate on Enlyterx.com
A complete whole food vitamin supplement with folate
Lecithin with choline, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidic acid
A complete diverse mineral supplement
B. Activity Ancillary:
Adequate rest each night without exposure to artificial light or energy sources, appliances, electronics, or communication EMF
Short duration exercise each day using some level of resistance between 5 and 15 minutes, focusing on each major anatomical factor with pauses if noticeable stress emerges for comfortable achievement of repetition objectives
EMF protection minimum includes covering all power plugins and power outlets with EMF safe tape or duct tape, placing EMF absorbing stickers or tape on any electronic device or appliance, covering windows with EMF safe coverings or applying EMF stickers or tape every 12 inches of window space, and using weather sealing capability or duct tape with wood/cardboard/plastic/plexiglass to cover any impaired locations on housing where atmospheric fields can enter, including covering key unused keyholes and spaces under doors or windows.
C. Custom Formulation Supplement:
Lecithin as Choline 50 mg, Phosphatidylcholine 100 mg, Phosphatidylethanolamine 100 mg, Phosphatidylserine 100 mg, Phosphatidylinositol 100 mg, phosphatidic acid 50 mg, and an emulsification context such as olive oil 50 mg.
Grapeseed extract 50 mg
Olive oil extract 50 mg
Probiotic with Bifido Infantis or with a diverse group of probiotics, such as the product Align which exhibits bifido at 4 mg
Arginine 50 mg, L-citrulline 50 mg, L-ornithine 50 mg
Diverse mineral supplement and trace mineral supplement at these levels (clinical configuration at 125% of RDA)
Supplemental, Therapeutic, and Clinical Objectives
Item A: Assurance of the CDP ethanolamine pathway, PEMT, at between 30 and 40 percent of the capacity of the CDP choline pathway.
Item B: Optimal NAD+/NADH ratio, optimal hydrogen anion multiplicity availability in the NAD+/NADH anion gap, including regulating NAD+ attrition by NADase activity, optimal NAD+ availability, optimal NADH availability, and optimal hydrogen anion density in tissue, along with methylene cysteine (clinically known as HCY) lower than 6 μm/L to about 3.7 μm/L, and optimal s adenosyl methylene cysteine density at lower than 0.012 μm/L.
Item C: CH2 methylene + e- from natural light or therapeutic light = excited CH2 enabling foundational polymerization of ribose in DNA, RNA, fatty acids, alkanes, e- carriers, NAD(H), and NADP(H).
Item D: Counteract T M A O, diminishing what is the most or among the most indicative causal factors to sudden diminished outcome, sudden abated being, and diminished behavior.
These factors implore, suggest, advise, and presume the continued or more prevalent exhibition of interactions and consultation with providers of care, facilities that provide care, and the foundations and institutions that support research and development which improves care and care outcomes. Prioritization by civilizations of the modalities through which human physiological and behavioral outcomes are improved and assured is essential.
Cognitive, Behavioral, Compulsion, Addiction
A. Interventional Ibogaine with magnesium or toxicity diminishment factor as clinically indicated.
B. Agmatine, Lecithin, Vitamin K2, curcumin, or an iNOS/NOS 2 inhibitor, EMF protection.
C. Narcan.
D. Typical therapies in these contexts, emerging therapies, review complete daily regimen, disease or diminished status regimen, simplified factors insight version, therapeutic API A, therapeutic API B, therapeutic API C, foundational document 1, foundational document 2, foundational document 3, destabilizing oncology document, and the other documents in this compendium of research.
Counteracting Disease or Diminished Status Regimen
A. Daily regimen.
B. Active hexose correlated compound.
C. Se methylselenocysteine, methyl selenic acid, methyl selenol, sodium selenite as Na2SeO3, selenomethionine as C5H11NO2Se.
D. Methylsulfonylmethane.
E. Berberine.
F. Curcumin.
G. 2plamitoylphosphatidylcholine.
H. Treatment for hyponatremia, low sodium, and low iodide, regardless of diagnosis and particularly with oncology.
I. Nope 1.
J. Nope 2 or other Nope metabolites include that with DHA, oleoylate, palmitate, extended length arachidonic acid, omega-3, and ether-linked fatty acid species.
K. Topical geranyl choline.
L. Topical dimethylsulfide DMSO.
M. Phage therapy.
N. Favipiravir or other antiviral.
O. Crispr genetic therapy.
P. G quadruplex stabilization.
Q. Regenerate renal structure with Usag1 inhibition.
R. Regenerate cardiac complex with Agrin grafts to matrix.
S. Regenerate dental structures by inhibiting Usag1 and increasing BMP7.
T. Stabilize renal conditions using inhibitors of CD20, GLP1 therapy, and kidney stuff by golden standards.
U. L-arginine, L-citrulline, L-ornithine, agmatine, spermidine, spermine.
V. Nattokinase.
W. Serrapeptase.
X. Sapropterin tetrahydrobiopterin, Kuvan.
Y. Inhibition of mitophagy or inhibition of autophagy to counteract pathology-promoting exosomes, including toxic senescence phenotype, SASP, which can be promoted by mTorc1 or other factors.
Z. Beneficial interventional therapy using therapeutic exosomes and secretagogues.
These factors implore, suggest, advise, and presume the continued or more prevalent exhibition of interactions and consultation with providers of care, facilities that provide care, the foundations and institutions that support research and development which improves care and care outcomes, prioritization by civilizations of the modalities through which human physiological and behavioral outcomes are improved and assured.
Enhanced Insight
This review has found that in early gestation, before gestational nutrition transfer tissue emerges and in epithelium layers foundational enough to diminish nutrient obtainment, the HRE, serum, reactive oxygen species, and thermodynamic response elements are activated both to prevent apoptosis and repress differentiation among stem and pluripotent phenotypes. Reactive oxygen species promote differentiation. During emergence from stemness, reactive oxygen species are exhibited and promote differentiation. However, inadequate oxygen or inadequate nutrients causes accumulation of HIF1 alpha, and HIF1 beta is activated by environmental pollution, atmospheric particulate, aquatic particulate, xenobiotics, nutritional particulate, and other detrimental factors, along with bona fide inadequate oxygen. Accumulation of HIF1 alpha activates the response elements. Activation of HIF1 beta occurs through pollutants, xenobiotics, and other factors and results in the movement of the HIF1 alpha/HIF1 beta complex into the nucleus, enabled by HIF1 beta, which is known as the aryl hydrocarbon receptor transport factor. There are other pathways that can activate these response elements. Molecular conditions can mimic hypoxia. Methylene cysteine above 3.7 μm/L can be interpreted by physiology as hypoxia; pH diverged from optimal can be interpreted as hypoxia, and other toxic and deteriorating conditions can also be interpreted as hypoxia. HRE response elements prevent stem and pluripotent phenotypes from being fully surmounted and prevent complete differentiation from fully occurring. SP1, AP1, and cystathionine beta synthase are all expressed through the HRE response element. AP1 promotes senescence by repressing telomerase, while SP1 surmounts senescence by increasing telomerase to protect GC dense regions of DNA, including telomeres and including regions where extra copies of SP1 are obscured in G quadruplexes. Inhibition of PEMT and an increase in choline kinase and the CDP choline pathway can mimic, be interpreted as, and be exhibited along with HRE response element activation. The dynamics of PEMT inhibition and P53 increases cause a syndrome in which stem and pluripotent phenotypes emerge to exhibit incomplete generation and perpetual stemness along with perpetually incomplete differentiation. A review of every oncology phenotype was found to involve HRE and linked response elements repressing apoptosis, repressing senescence, perpetuating stemness, preventing maturation, preventing development, causing rapid development, causing persistent non-resolution phase signaling.
This review found that these same factors, particularly methylene cysteine, but also include about 1 percent or more content of microplastics in neurological tissue, were causal to at least 98 percent of Alzheimer's, if not 100 percent, and have been ignored in modalities that assure the exhibition of diminished outcomes. This review found that repressing methylene cysteine, TMAO, EMF exposure, exposure to the internet—including having one's information exhibited on the internet or having one's information in any information system or data construct without a cypher and without being separated from information about diminished outcomes—all are able to massively deteriorate disease while assurance of phospholipids, choline, B12 vitamin, omega-3/6/7/9/11, other vitamins, minerals, trace minerals, stability, housing, stable access to healthy foods, access to clean water, emotional stability, diminished effects of conditions that promote increased cortisol, preventing any system from benefiting from the exhibition of diminished outcomes, and other factors that reasonably constitute achievement for which human incipiently derived civilization, all are able to massively prevent disease, diminished behavioral outcomes, diminished physiological outcomes, adverse health status, neurological deterioration, and other diminished outcomes.
The literature presents that obscuring the sulfur of methylene cysteine prevents its oxidation and results in the accumulation of methylene cysteine, which then increases the bioavailability of methylene cysteine to also increase the production of methylene cysteine thiolactone by methionyltRNA synthetase. The literature presents deficiency of methylene cysteine thioretinamide, which is produced from methylene cysteine and retinoic acid, as being deficient when methylene cysteine oxidation is impaired. However, cystathionine beta synthase and cystathionine gamma lyase both are known to oxidize sulfur from methylene cysteine, while oxidation of sulfur from methionine is a transsulfuration pathway event that is competed with by INMT inversion of S adenosyl methionine and S adenosyl methylene cysteine, methionine synthase conversion of methylene cysteine to methionine, BHMT conversion of methylene cysteine to methionine, BHMT2 conversion of methylene cysteine to methionine, and the controversial THMT enzyme known since 1882, which produces methionine and the pivotal methylthioglycolic acid (presented as the center of medicinal chemistry) used to produce vast aspects of therapeutics since the 1880s.
Organic synthesis produces thioretinamide from methylene cysteine thiolactone and retinol using organic synthesis, followed by two molecules of retinamide interacting with cobalamin to produce thioretinaco, which occurs cleanly if vitamin B12 of cobalamin is not in a synthetic version of hydroxo or the metabolic toxin cyano, which each require molecules of S adenosyl methionine to be used to translate hydroxo and cyano into methylcobalamin. This context is more intricately complicated if individuals are on a low salt nutritional regimen because this prevents absorption of vitamin B12, explaining why some versions of oncology are known to follow hyponatremia diagnosis by between 100 percent and 90 percent. This context is also complicated by the exhibition in some contexts or in earlier eras, possibly even now, of striates included in the manufacturing of table salt, which can cause striated vascular injury, promote non-resolution phase, cause increases in cholesterol to coat vasculature, and therefore cause misrepresentation of sodium and cholesterol in disease, while cholesterol comprises up to 87 percent of the foundational biological compartment, and it is oxidized cholesterol that might more accurately present clinical nuances of pathology in this context. Inadequate sodium prevents sodium from accompanying lithium, as high vapor pressure atoms, in eluting hydrogen anion from other elemental hydrogen anion complexes that have low vapor pressure. Levels of H2e1p)- assist in the integration of hydrogen anion into physiology and physiological structures to promote optimal NAD+/NADH ratio, optimal hydrogen anion multiplicity availability in the NAD+/NADH anion gap, including regulating NAD+ attrition by NADase activity, optimal NAD+ availability, optimal NADH availability, and optimal hydrogen anion density in tissue, along with methylene cysteine (clinically known as HCY) lower than 6 μm/L to about 3.7 μm/L, and optimal S adenosyl methylene cysteine density at lower than 0.012 μm/L.
Methylene cysteine is optimal near, about, or at 3.7 μm/L (statistically 6 μm/L or lower) and when adenosyl methylene cysteine is lower than 0.012 μm/L.
These factors implore, suggest, advise, and presume the continued or more prevalent exhibition of interactions and consultation with providers of care, facilities that provide care, the foundations and institutions that support research and development which improves care and care outcomes, prioritization by civilizations of the modalities through which human physiological and behavioral outcomes are improved and assured.
Comments